1. Home
  2. IVT vs ADPT Comparison

IVT vs ADPT Comparison

Compare IVT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InvenTrust Properties Corp.

IVT

InvenTrust Properties Corp.

HOLD

Current Price

$32.10

Market Cap

2.4B

Sector

Real Estate

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.80

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVT
ADPT
Founded
2005
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.3B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
IVT
ADPT
Price
$32.10
$13.80
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$32.50
$17.78
AVG Volume (30 Days)
380.5K
1.4M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
3.14%
N/A
EPS Growth
647.37
63.89
EPS
0.07
N/A
Revenue
$299,169,000.00
$276,976,000.00
Revenue This Year
$8.42
$3.98
Revenue Next Year
$5.25
$22.72
P/E Ratio
$452.71
N/A
Revenue Growth
9.20
54.77
52 Week Low
$26.52
$8.38
52 Week High
$33.19
$20.76

Technical Indicators

Market Signals
Indicator
IVT
ADPT
Relative Strength Index (RSI) 52.93 46.84
Support Level $30.31 $12.22
Resistance Level $32.91 $15.38
Average True Range (ATR) 0.65 0.66
MACD -0.09 0.02
Stochastic Oscillator 41.08 29.79

Price Performance

Historical Comparison
IVT
ADPT

About IVT InvenTrust Properties Corp.

InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: